The company has received approval from Health Canada to conduct the CAN-PRIME Study, according to a Nov. 20 news release. This study aims to evaluate the safety of Neuralink’s implant and surgical robot while testing the effectiveness of its brain-computer interface (BCI).
The BCI is designed to enable individuals with quadriplegia to control external devices using their thoughts. The trial is open to Canadian residents with limited or no use of both hands due to ALS or cervical spinal cord injury.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.